These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

355 related items for PubMed ID: 36396553

  • 1. Cytotoxic activity of anti-mucin 1 chimeric antigen receptor T cells expressing PD-1-CD28 switch receptor against cholangiocarcinoma cells.
    Supimon K, Sangsuwannukul T, Sujjitjoon J, Chieochansin T, Junking M, Yenchitsomanus PT.
    Cytotherapy; 2023 Feb; 25(2):148-161. PubMed ID: 36396553
    [Abstract] [Full Text] [Related]

  • 2. Anti-mucin 1 chimeric antigen receptor T cells for adoptive T cell therapy of cholangiocarcinoma.
    Supimon K, Sangsuwannukul T, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, Wongkham S, Junking M, Yenchitsomanus PT.
    Sci Rep; 2021 Mar 18; 11(1):6276. PubMed ID: 33737613
    [Abstract] [Full Text] [Related]

  • 3. CD19-specific CAR T Cells that Express a PD-1/CD28 Chimeric Switch-Receptor are Effective in Patients with PD-L1-positive B-Cell Lymphoma.
    Liu H, Lei W, Zhang C, Yang C, Wei J, Guo Q, Guo X, Chen Z, Lu Y, Young KH, Lu Z, Qian W.
    Clin Cancer Res; 2021 Jan 15; 27(2):473-484. PubMed ID: 33028589
    [Abstract] [Full Text] [Related]

  • 4. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
    Zolov SN, Rietberg SP, Bonifant CL.
    Cytotherapy; 2018 Oct 15; 20(10):1259-1266. PubMed ID: 30309710
    [Abstract] [Full Text] [Related]

  • 5. Inhibition of T-cell-mediated immune response via the PD-1/ PD-L1 axis in cholangiocarcinoma cells.
    Suriyo T, Fuangthong M, Artpradit C, Ungtrakul T, Sricharunrat T, Taha F, Satayavivad J.
    Eur J Pharmacol; 2021 Apr 15; 897():173960. PubMed ID: 33617828
    [Abstract] [Full Text] [Related]

  • 6. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells.
    Sangsuwannukul T, Supimon K, Sujjitjoon J, Phanthaphol N, Chieochansin T, Poungvarin N, Wongkham S, Junking M, Yenchitsomanus PT.
    Int Immunopharmacol; 2020 Dec 15; 89(Pt B):107069. PubMed ID: 33242709
    [Abstract] [Full Text] [Related]

  • 7. Enhanced antitumor efficacy, proliferative capacity, and alleviation of T cell exhaustion by fifth-generation chimeric antigen receptor T cells targeting B cell maturation antigen in multiple myeloma.
    Yuti P, Sawasdee N, Natungnuy K, Rujirachaivej P, Luangwattananun P, Sujjitjoon J, Yenchitsomanus PT.
    Biomed Pharmacother; 2023 Dec 15; 168():115691. PubMed ID: 37844355
    [Abstract] [Full Text] [Related]

  • 8. Genetically Engineered CLDN18.2 CAR-T Cells Expressing Synthetic PD1/CD28 Fusion Receptors Produced Using a Lentiviral Vector.
    Lee HJ, Hwang SJ, Jeong EH, Chang MH.
    J Microbiol; 2024 Jul 15; 62(7):555-568. PubMed ID: 38700775
    [Abstract] [Full Text] [Related]

  • 9. Precision immunotherapy for cholangiocarcinoma: Pioneering the use of human-derived anti-cMET single chain variable fragment in anti-cMET chimeric antigen receptor (CAR) NK cells.
    Chiawpanit C, Wathikthinnakorn M, Sawasdee N, Phanthaphol N, Sujjitjoon J, Junking M, Yamabhai M, Panaampon J, Yenchitsomanus PT, Panya A.
    Int Immunopharmacol; 2024 Jul 30; 136():112273. PubMed ID: 38810311
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dual-function chimeric antigen receptor T cells targeting c-Met and PD-1 exhibit potent anti-tumor efficacy in solid tumors.
    Yuan X, Sun Z, Yuan Q, Hou W, Liang Q, Wang Y, Mo W, Wang H, Yu M.
    Invest New Drugs; 2021 Feb 30; 39(1):34-51. PubMed ID: 32772342
    [Abstract] [Full Text] [Related]

  • 13. PD-1 silencing improves anti-tumor activities of human mesothelin-targeted CAR T cells.
    Liu G, Zhang Q, Li D, Zhang L, Gu Z, Liu J, Liu G, Yang M, Gu J, Cui X, Pan Y, Tian X.
    Hum Immunol; 2021 Feb 30; 82(2):130-138. PubMed ID: 33341289
    [Abstract] [Full Text] [Related]

  • 14. PD-1-CD28-enhanced receptor and CD19 CAR-modified tumor-infiltrating T lymphocytes produce potential anti-tumor ability in solid tumors.
    Chen X, Zhao X, Mou X, Zhao J, Zhang Z, Zhang X, Huang J, Liu Y, Wang F, Zhang M, Wang L, Gu W, Zhang Y.
    Biomed Pharmacother; 2024 Jun 30; 175():116800. PubMed ID: 38788547
    [Abstract] [Full Text] [Related]

  • 15. Strong capacity of differentiated PD-L1 CAR-modified UCB-CD34+ cells and PD-L1 CAR-modified UCB-CD34+-derived NK cells in killing target cells and restoration of the anti-tumor function of PD-1-high exhausted T Cells.
    Ghaedrahmati F, Akbari V, Seyedhosseini-Ghaheh H, Esmaeil N.
    Stem Cell Res Ther; 2024 Aug 13; 15(1):257. PubMed ID: 39135206
    [Abstract] [Full Text] [Related]

  • 16. Chimeric Antigen Receptor T Cells Targeting Integrin αvβ6 Expressed on Cholangiocarcinoma Cells.
    Phanthaphol N, Somboonpatarakun C, Suwanchiwasiri K, Chieochansin T, Sujjitjoon J, Wongkham S, Maher J, Junking M, Yenchitsomanus PT.
    Front Oncol; 2021 Aug 13; 11():657868. PubMed ID: 33763382
    [Abstract] [Full Text] [Related]

  • 17. Immune Checkpoint Blockade via PD-L1 Potentiates More CD28-Based than 4-1BB-Based Anti-Carbonic Anhydrase IX Chimeric Antigen Receptor T Cells.
    de Campos NSP, de Oliveira Beserra A, Pereira PHB, Chaves AS, Fonseca FLA, da Silva Medina T, Dos Santos TG, Wang Y, Marasco WA, Suarez ER.
    Int J Mol Sci; 2022 May 13; 23(10):. PubMed ID: 35628256
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Functional enhancement of mesothelin-targeted TRuC-T cells by a PD1-CD28 chimeric switch receptor.
    McCarthy D, Lofgren M, Watt A, Horton H, Kieffer-Kwon P, Ding J, Kobold S, Baeuerle PA, Hofmeister R, Gutierrez DA, Tighe R.
    Cancer Immunol Immunother; 2023 Dec 13; 72(12):4195-4207. PubMed ID: 37848682
    [Abstract] [Full Text] [Related]

  • 20. Co-expression of a PD-L1-specific chimeric switch receptor augments the efficacy and persistence of CAR T cells via the CD70-CD27 axis.
    Qin L, Cui Y, Yuan T, Chen D, Zhao R, Li S, Jiang Z, Wu Q, Long Y, Wang S, Tang Z, Pan H, Li X, Wei W, Yang J, Luo X, Zhang Z, Tang Q, Liu P, Weinkove R, Yao Y, Qin D, Thiery JP, Li P.
    Nat Commun; 2022 Oct 13; 13(1):6051. PubMed ID: 36229619
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.